Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Interest Expense : $-0.09 Mil (TTM As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cotinga Pharmaceuticals's interest expense for the three months ended in Jan. 2020 was $ -0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jan. 2020 was $-0.09 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cotinga Pharmaceuticals's Operating Income for the three months ended in Jan. 2020 was $ -0.36 Mil. Cotinga Pharmaceuticals's Interest Expense for the three months ended in Jan. 2020 was $ -0.03 Mil. Cotinga Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cotinga Pharmaceuticals Interest Expense Historical Data

The historical data trend for Cotinga Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Interest Expense Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Interest Expense

Get a 7-Day Free Trial

-0.05

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
Interest Expense	Get a 7-Day Free Trial															-	-	-0.02	-0.03	-0.03

Cotinga Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jan. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

Cotinga Pharmaceuticals (OTCPK:COTQF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cotinga Pharmaceuticals's Interest Expense for the three months ended in Jan. 2020 was $-0.03 Mil. Its Operating Income for the three months ended in Jan. 2020 was $-0.36 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jan. 2020 was $0.00 Mil.

Cotinga Pharmaceuticals's Interest Coverage for the quarter that ended in Jan. 2020 is calculated as

Cotinga Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019